Investment in rare disease biotechs has increased following renewal of the FDA’s Priority Review Voucher (PRV) programme, according to SynaptixBio, but the United States remains dominant compared to the UK. In February 2026, the PRV programme was signed into law and will remain in place until reviewed again in September… Read More
A new research report has found that investing £15 billion ($20 billion) in UK university spinouts over the next 10 years could leverage a further £27 billion ($39 billion) of co-investment, leading to the creation of over 1700 additional spinouts and 56,000 skilled jobs, boosting UK science on the global… Read More
This is the latest episode of the free DDW narrated podcast, titled “UK Spotlight: Innovation and discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Where is the drug discovery expertise happening in the UK?”, “From the top: Dr… Read More
Aviva Capital Partners (ACP) and developer Socius have unveiled plans for a new £1 ($1.3) billion development to create a leading centre for cancer research in Sutton, London, UK. The development will be delivered on a 12-acre site at the London Cancer Hub, adjacent to The Institute… Read More
Listen to this article on the DDW Podcast: The United Kingdom has established itself as a hub for drug discovery expertise worldwide. Here, DDW’s Megan Thomas highlights the research taking place and where this is happening. The Golden Triangle Though the UK is… Read More
